Background: To establish a nomogram model for predicting chemotherapy-induced nausea and vomiting (CINV) in patients with gynecological malignancies based on relevant risk factors.
Methods: This retrospective study included patients with gynecological malignancies hospitalized in the oncology department of Affiliated People's Hospital of Jiangsu University between February 2020 and October 2021. Patients were divided into a training set (between February 2020 and December 2020) and a validation set (between January 2021 and October 2021). Basic and clinical characteristics were collected and analyzed by univariate and multivariate logistic regression. A nomogram was constructed and assessed with the receiver operating characteristic curve (ROC). We have also conducted an external validation using data from 297 patients with gynecological malignancies admitted to two oncology wards at our hospital (140 patients from Ward 1 and 157 patients from Ward 2).
Results: This study comprised 148 patients in the training set and 148 in the validation set. Multivariate analysis revealed age <60 years (OR (Odds Ratio) = 4.001, 95% CI (Confidence interval) 1.349-11.872, P = 0.012), presence of motion sickness (OR = 3.841, 95% CI 1.200-12.296, P = 0.023), history of pregnancy-related vomiting (OR = 4.067, 95% CI 1.203-13.751, P = 0.024), and the use of moderate/high emetogenic chemotherapy drugs (OR = 10.299, 95% CI 2.858-37.115, P < 0.001) as independent risk factors for CINV. These factors were incorporated into a nomogram, which exhibited an area under the ROC (AUC) of 0.844, with a sensitivity of 81.4% and specificity of 80.0% at the optimal cut-off point of 159.48. The AUC for validation was 0.945, with sensitivity and specificity of 91.5% and 87.1% at the optimal cut-off point of 159.48, respectively. The external validation results showed an AUC of 0.704 (95% CI: 0.648-0.755), with a sensitivity of 93.33% and specificity of 48.15% (P = 0.001).
Conclusion: The developed nomogram, incorporating age, moderate/high emetogenic chemotherapy drugs, motion sickness, and pregnancy vomiting history, showed good discrimination for CINV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jjco/hyaf042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification and mechanism analysis of biomarkers related to butyrate metabolism in COVID-19 patients.
Ann Med
December 2025
Department of Assisted Reproductive Centre, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, China.
Background: Butyrate may inhibit SARS-CoV-2 replication and affect the development of COVID-19. However, there have been no systematic comprehensive analyses of the role of butyrate metabolism-related genes (BMRGs) in COVID-19.
Methods: We performed differential expression analysis of BMRGs in the brain, liver and pancreas of COVID-19 patients and controls in GSE157852 and GSE151803.
Consensus statement on pain management for pregnant patients with opioid use disorder from the Society for Obstetric Anesthesia and Perinatology, Society for Maternal-Fetal Medicine, and American Society of Regional Anesthesia and Pain Medicine.
Am J Obstet Gynecol
March 2025
Friends Research Institute, Baltimore, MD.
Pain management in pregnant and postpartum people with an opioid use disorder requires a balance among the risks associated with opioid tolerance, including withdrawal or return to opioid use, considerations around the social needs of the maternal-infant dyad, and the provision of adequate pain relief for the birth episode that is often characterized as the worst pain a person will experience in their lifetime. This multidisciplinary consensus statement from the Society for Obstetric Anesthesia and Perinatology, the Society for Maternal-Fetal Medicine, and the American Society of Regional Anesthesia and Pain Medicine provides a framework for pain management in obstetrical patients with opioid use disorder. The purpose of this consensus statement is to provide practical and evidence-based recommendations and is targeted to healthcare providers in obstetrics and anesthesiology.
View Article and Find Full Text PDFEffect of Home-based Virtual Reality Training on Upper Extremity Recovery in Patients with Stroke: Systematic Review.
J Med Internet Res
March 2025
Rehabilitation Lab of Mix Reality, Shenzhen Hospital, Southern Medical University, Shenzhen, CN.
Background: Stroke is a leading cause of long-term disability, often resulting in upper extremity dysfunction. Traditional rehabilitation methods often face challenges such as limited patient access to resources and lack of sustained motivation. Home-based virtual reality (VR) training is gaining traction as an innovative, sustainable and interactive alternative.
View Article and Find Full Text PDFPotential New Tumors Associated with Hereditary Breast and Ovarian Cancer (HBOC).
Keio J Med
March 2025
Center for Hereditary Breast and Ovarian Cancer Syndrome, Keio University Hospital, Tokyo, Japan.
Hereditary breast and ovarian cancer syndrome (HBOC) is traditionally associated with mutations in the BRCA1 and BRCA2 genes, predominantly impacting breast, ovarian, pancreatic, and prostate cancers. However, recent research suggests that these mutations may also predispose carriers to a broader spectrum of malignancies, including biliary tract, cervical, colorectal, endometrial, esophageal, and gastric cancers. This review presents findings from extensive datasets, including a significant study from a nationwide Japanese biobank that examined cancer risks in 63,828 patients and 37,086 controls.
View Article and Find Full Text PDFCarriers of a single cystic fibrosis transmembrane conductance regulator pathogenic variant and COVID-19 in pregnancy: A retrospective cohort study.
J Obstet Gynaecol Can
March 2025
Creighton University School of Medicine, Omaha Campus, Department of Clinical Research and Evaluative Sciences).
COVID-19 outcomes are worse in non-pregnant patients that are cystic fibrosis carriers; however, no studies have examined COVID-19 outcomes in pregnant patients that are cystic fibrosis carriers. We evaluated the cystic fibrosis carrier status of pregnant patients with COVID-19 in three geographical regions in the United States and compared outcomes between non-carriers and carriers. Out of 2430 pregnant patients with COVID-19, 229 had a cystic fibrosis screen.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!